GSK Brings Next-Generation Vaccine Technology In-House with Okairos Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 6 (Table of Contents)
Published: 22 Jun-2013
DOI: 10.3833/pdr.v2013.i6.1953 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
GlaxoSmithKline (GSK) has made a long-term investment in its vaccines business by acquiring the Swiss company Okairos, which was spun out from Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS